Ascletis announces positive topline results of phase ib studies of asc47 monotherapy in australia and u.s. fda clearance of ind application for asc47 in combination with semaglutide

Asc47, an adipose-targeted muscle-preserving weight loss drug candidate for the treatment of obesity, demonstrated a half-life of up to 26 days and 40 days, respectively, in phase ib single subcutaneous injection studies in healthy subjects with elevated low-density lipoprotein cholesterol ( ldl-c) and patients with obesity, supporting once-monthly to once-bimonthly administration. asc47 was safe and well tolerated in both healthy subjects with elevated ldl-c and patients with obesity.
ASC Ratings Summary
ASC Quant Ranking